Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States ...

Eli Lilly's weight-loss jab Mounjaro has been cleared for rollout by the NHS in England, with around 3.4 million people eligible, but will be made available in stages to limit the financial impact.

Eli Lilly's weight-loss drugs include Mounjaro and Zepbound.Sandy Huffaker for The Washington Post/Getty Images Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.